Live Attenuated Influenza Vaccine May Thwart Acute Otitis Media in Young Children: Presented at PAS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Live Attenuated Influenza Vaccine May Thwart Acute Otitis Media in Young Children: Presented at PAS

By Jill Stein

BALTIMORE, Md -- May 5, 2009 -- Live attenuated influenza vaccine (LAIV) may reduce the burden of influenza-associated acute otitis media (AOM) in young children, researchers reported on May 5 at the 2009 Pediatric Academic Societies (PAS) Annual Meeting.

Stan L. Block, MD, Kentucky Pediatric and Adult Research, Inc., Bardstown, Kentucky, and colleagues analysed data to determine whether intranasal LAIV prevents AOM associated with culture-confirmed influenza due to matched strains.

For the analysis, they used data from 6 randomised, double-blind, placebo-controlled trials and 2 trivalent inactivated vaccine (TIV)-controlled studies that evaluated LAIV efficacy against AOM associated with culture-confirmed intranasal swab.

AOM was defined clinically by the presence of an abnormal tympanic membrane, suggesting effusion in the middle ear cavity, with signs or symptoms consistent with acute infection. The condition also had to be diagnosed by a healthcare provider who prescribed antibiotics for the infection.

Studies were conducted in children aged 6 to 71 months, most of whom were aged younger than 35 months.

Results in of more than 15,000 patients showed that LAIV decreased influenza-associated AOM caused by matched strains by 73% to 98%.

The incidence of influenza-associated AOM was lower in patients assigned to LAIV than in TIV recipients.

"This finding was largely due to the higher efficacy of LAIV against influenza illness compared with TIV or placebo," Dr. Block explained. "These data suggest that LAIV reduces the burden of influenza-associated AOM in young children."

Funding for this study was provided by MedImmune, LLC.

[Presentation title: Live Attenuated Influenza Vaccine and Reduction in Influenza-Associated Acute Otitis Media in Children 6-71 Months. Abstract 5529.504]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities